Nov. 1 (Bloomberg) -- Abbott Laboratories is likely to show regulators that its new heart stent can open clogged arteries better than devices already on the market. Doctors and investors may not be impressed. Research released last week showed that Xience prevented 50 percent more deaths, heart attacks and repeat procedures than Boston Scientific Corp.'s Taxus, the best-selling stent in the U.S. The study failed to show Xience had fewer complications than Taxus or Johnson & Johnson’s Cypher, products whose sales plunged 40 percent this year after being linked to lethal clots.
